Here, we report ELAINE 2 data with longer patient follow up (Jan 31, 2023).Methods:In this open-label, phase 2, single-arm study, 29 women withmESR1, ER+/HER2- mBC that progressed on prior ET took oral LAS 5 mg/day and Abema 150 mg BID until disease progression/toxicity. The ...